Why One Analyst Thinks Johnson & Johnson Reaches $280

"HSBC argues that the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter. That thesis has real data behind it. The VIX currently sits at 23.51, in the elevated uncertainty range, and is up 14.1% over the past month, reinforcing the case for rotating into defensive sectors."

"Oncology franchise compounding: DARZALEX grew 26.6% and CARVYKTI surged 65.8% in Q4 2025, with new Phase 1 bladder cancer data for erda-iDRS showing an 89% complete response rate. A deepening oncology pipeline creates durable, multi-year revenue streams that could support sustained revenue growth."

"Orthopaedics separation unlocking value: J&J's planned separation of DePuy Synthes within 18-24 months sharpens focus on higher-growth segments including Oncology, Neuroscience, and Cardiovascular. Leaner business structures historically support multiple expansion, a potential catalyst for multiple expansion."

Johnson & Johnson has significantly outperformed the healthcare sector, with shares up 48% over the past 12 months and currently trading around $241. HSBC analyst Morten Herholdt raised his price target to $280, citing three primary catalysts: strong oncology franchise performance with DARZALEX growing 26.6% and CARVYKTI surging 65.8%, the planned separation of DePuy Synthes within 18-24 months to focus on higher-growth segments, and the company's 63-year dividend increase streak providing reliable retirement income. Market conditions favor defensive healthcare investments due to elevated geopolitical risks, macro uncertainty reflected in elevated VIX levels, and lower AI disruption exposure compared to other sectors.

Read at 24/7 Wall St.